Infliximab (Remicade) for ulcerative colitis - horizon scanning review
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Infliximab (Remicade) for ulcerative colitis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005
Authors' objectives
This study aims to summarise the currently available evidence on Infliximab (Remicade) for ulcerative colitis.
Authors' conclusions
Infliximab (Remicade), an anti-tumor necrosis factor (TNF) agent, is in development for the treatment of active ulcerative colitis (UC). Two phase III trials (364 patients in each) that reported at conference in May 2005, demonstrated that infliximab met its primary and secondary endpoints of clinical response, clinical remission and mucosal healing in patients with moderate to severe active UC who were unresponsive to at least one standard therapy. A double-blind trial in 45 patients demonstrated that a single infusion of infliximab is effective, at 3 months, in acutely ill in-patients with fulminant UC refractory to intravenous steroids.
Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk